OTCM
PURE
Market cap8mUSD
Jul 10, Last price
0.08USD
1D
0.00%
1Q
33.33%
Jan 2017
-90.83%
Name
PURE Biosciences Inc
Chart & Performance
Profile
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | 2016‑07 | 2015‑07 | |
Income | ||||||||||
Revenues | 1,963 4.58% | 1,877 1.30% | 1,853 -52.81% | |||||||
Cost of revenue | 1,113 | 1,203 | 1,172 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 850 | 674 | 681 | |||||||
NOPBT Margin | 43.30% | 35.91% | 36.75% | |||||||
Operating Taxes | 10 | 6 | ||||||||
Tax Rate | 1.48% | 0.88% | ||||||||
NOPAT | 850 | 664 | 675 | |||||||
Net income | (3,350) -15.43% | (3,961) 13.27% | (3,497) 50.80% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 3,500 | |||||||||
BB yield | -19.73% | |||||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | 2,949 | 1,021 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 2,525 | (74) | (3,391) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (2,531) | (3,278) | (2,418) | |||||||
CAPEX | (33) | (81) | ||||||||
Cash from investing activities | (33) | (81) | ||||||||
Cash from financing activities | 1,785 | 1,015 | 3,500 | |||||||
FCF | 1,058 | 1,063 | 871 | |||||||
Balance | ||||||||||
Cash | 424 | 1,095 | 3,391 | |||||||
Long term investments | ||||||||||
Excess cash | 326 | 1,001 | 3,298 | |||||||
Stockholders' equity | (135,476) | (132,126) | (128,170) | |||||||
Invested Capital | 135,561 | 133,419 | 132,079 | |||||||
ROIC | 0.63% | 0.50% | 0.52% | |||||||
ROCE | 1,000.00% | 52.13% | 17.42% | |||||||
EV | ||||||||||
Common stock shares outstanding | 111,856 | 111,404 | 88,835 | |||||||
Price | 0.08 -6.12% | 0.09 -57.44% | 0.20 -52.45% | |||||||
Market cap | 8,926 -5.74% | 9,469 -46.62% | 17,740 -51.55% | |||||||
EV | 11,451 | 9,395 | 14,349 | |||||||
EBITDA | 998 | 791 | 894 | |||||||
EV/EBITDA | 11.47 | 11.88 | 16.05 | |||||||
Interest | 155 | 14 | 6 | |||||||
Interest/NOPBT | 18.24% | 2.08% | 0.88% |